Changes in Beneficial Ownership · 4
Moderna, Inc.
MRNANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4.xml
Filing details
- Report period
- 2026-08-05
- Issuer
- Moderna, Inc.
- Issuer CIK
- 0001682852
- Trading symbol
- MRNA
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Bancel Stephane
- Reporting owner CIK
- 0001443340
- Relationship
- Director · Officer
- Officer title
- Chief Executive Officer
- Address
- C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE, MA, 02142
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-05 | M · Form 4[F1] | 499,246 | A | 19.15 | 6,687,037 | D |
| Common Stock | 2026-08-05 | S · Form 4[F1] | 147,473 | D | 56.21[F2] | 6,539,564 | D |
| Common Stock | 2026-08-05 | S · Form 4[F1] | 124,838 | D | 56.96[F3] | 6,414,726 | D |
| Common Stock | 2026-08-05 | S · Form 4[F1] | 39,891 | D | 58.12[F4] | 6,374,835 | D |
| Common Stock | 2026-08-05 | S · Form 4[F1] | 187,044 | D | 58.79[F5] | 6,187,791 | D |
| Common Stock | 2026-08-06 | M · Form 4[F1] | 252,469 | A | 19.15 | 6,440,260 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 9,210,686 | I | See Footnote[F6] |
| Common Stock | 6,564,880 | I | See Footnote[F7] |
Table key
- I
- Indirect
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 19.15 | 2026-08-05 | M · Form 4[F1] | 370,853 | D | 0 | [F8] | 2026-08-10 | Common Stock | 370,853 | 187,541 | D |
| Stock Option (Right to Buy) | 19.15 | 2026-08-05 | M · Form 4[F1] | 128,393 | D | 0 | [F8] | 2026-08-10 | Common Stock | 128,393 | 64,928 | D |
| Stock Option (Right to Buy) | 19.15 | 2026-08-06 | M · Form 4[F1] | 187,541 | D | 0 | [F8] | 2026-08-10 | Common Stock | 187,541 | 0 | D |
| Stock Option (Right to Buy) | 19.15 | 2026-08-06 | M · Form 4[F1] | 64,928 | D | 0 | [F8] | 2026-08-10 | Common Stock | 64,928 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10
- F2
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.58 to $56.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.↩ 1
- F3
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.59 to $57.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.↩ 1
- F4
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.60 to $58.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.↩ 1
- F5
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.61 to $59.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.↩ 1
- F6
- These shares are owned directly by Boston Biotech Ventures. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.↩ 1
- F7
- These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.↩ 1
Signature 1
- Signed
- /s/ James Dillon, as Attorney-in-Fact
- Date
- 2026-08-07
Company context
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna’s mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Current securities
Recent company filings
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementNov 16, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsNov 13, 2026
- 10-Q filingNov 6, 2026
- Results of Operations and Financial ConditionNov 6, 2026
- SCHEDULE 13G/A - filed by FMR LLC regarding Moderna, Inc.Nov 5, 2026